Ann Dermatol.  2018 Dec;30(6):704-707. 10.5021/ad.2018.30.6.704.

Parry-Romberg Syndrome Augmented by Hyaluronic Acid Filler

• Jo M
• Ahn H
• Ju H
• Park E
• Yoo J
• Kim MS
• Jue MS
• Choi K

• KMID: 2428927
• DOI: http://doi.org/10.5021/ad.2018.30.6.704

Abstract

Parry Romberg Syndrome (PRS), also known as idiopathic progressive hemifacial atrophy, is a rare neurocutaneous disorder characterized by loss of skin and subcutaneous fat of face, muscles, and bones causing unilateral atrophy. Most patients require only soft tissue augmentation although syndrome has varying grades of severity. In the majority of reported cases, it has been treated with surgical flap or autologous fat transplantation. However, these treatments need complicated surgical skills which take a lot of time and cost. Herein we report the first case of PRS augmented by hyaluronic acid (HA) filler in a 42-year-old female patient to suggest that HA filler could be a safe, simple, and even rational economic alternative to surgical treatment.

Keyword

Facial hemiatrophy; Filler; Hyaluronic acid

MeSH Terms

Adult
Atrophy
Facial Hemiatrophy*
Female
Humans
Hyaluronic Acid*
Muscles
Neurocutaneous Syndromes
Skin
Subcutaneous Fat
Surgical Flaps
Hyaluronic Acid

Figure

• 

  Fig. 1 Frontal views of the patient. At first visit, the patient shows overall atrophy of subcutaneous fat and hyperpigmentation on the right face (A). Immediately after injection by fanning technique. Total 7 ml of filler was injected (B). One month after the first filler injection, additional 1.5 ml hyaluronic acid (HA) filler was injected on the chin (C). One year after first injection, additional 3 ml HA filler was injected on the chin (D).

• 

  Fig. 2 Lateral views of the patient. At first visit, we planned to inject fillers in the direction of the arrows with fanning technique (A). After subcision with the cannula, total 7 ml of filler was injected via two holes on the cheek and chin (B). One month after the first filler injection (C). One year after first injection (D).

Reference

1. Hunstad JP, Shifrin DA, Kortesis BG. Successful treatment of Parry-Romberg syndrome with autologous fat grafting: 14-year follow-up and review. Ann Plast Surg. 2011; 67:423–425.

2. Balaji SM. Subdermal fat grafting for Parry-Romberg syndrome. Ann Maxillofac Surg. 2014; 4:55–59.

3. Agostini T, Spinelli G, Marino G, Perello R. Esthetic restoration in progressive hemifacial atrophy (Romberg disease): structural fat grafting versus local/free flaps. J Craniofac Surg. 2014; 25:783–787.

4. Alencar JC, Andrade SH, Pessoa SG, Dias IS. [Autologous fat transplantation for the treatment of progressive hemifacial atrophy (Parry-Romberg syndrome: case report and review of medical literatute)]. An Bras Dermatol. 2011; 86:4 Suppl 1. S85–S88. Portuguese.

5. Chang Q, Li J, Dong Z, Liu L, Lu F. Quantitative volumetric analysis of progressive hemifacial atrophy corrected using stromal vascular fraction-supplemented autologous fat grafts. Dermatol Surg. 2013; 39:1465–1473.

6. Myung Y, Lee YH, Chang H. Surgical correction of progressive hemifacial atrophy with onlay bone graft combined with soft tissue augmentation. J Craniofac Surg. 2012; 23:1841–1844.

7. Cox SE, Soderberg JM. Idiopathic hemifacial atrophy treated with serial injections of calcium hydroxylapatite. Dermatol Surg. 2010; 36:542–545.

8. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007; 56:257–263.

9. Chai G, Tan A, Yao CA, Magee WP 3rd, Junjun P, Zhu M, et al. Treating Parry-Romberg syndrome using three-dimensional scanning and printing and the anterolateral thigh dermal adipofascial flap. J Craniofac Surg. 2015; 26:1826–1829.

10. Yu-Feng L, Lai G, Zhi-Yong Z. Combined treatments of facial contour deformities resulting from Parry-Romberg syndrome. J Reconstr Microsurg. 2008; 24:333–342.

11. Al-Niaimi F, Taylor JA, Lyon CC. Idiopathic hemifacial atrophy treated with permanent polyacrylamide subdermal filler. Dermatol Surg. 2012; 38:143–145.

12. Park S, Park KY, Yeo IK, Cho SY, Ah YC, Koh HJ, et al. Investigation of the degradation-retarding effect caused by the low swelling capacity of a novel hyaluronic Acid filler developed by solid-phase crosslinking technology. Ann Dermatol. 2014; 26:357–362.

13. Bugge H, Negaard A, Skeie L, Bergersen B. Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients. HIV Med. 2007; 8:475–482.

14. Becker M, Balague N, Montet X, Calmy A, Salomon D, Toutous-Trellu L. Hyaluronic Acid filler in HIV-associated facial lipoatrophy: evaluation of tissue distribution and morphology with MRI. Dermatology. 2015; 230:367–374.

15. Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid- and lower face. Aesthet Surg J. 2006; 26(1s):S10–S17.

16. Lee BM, Han DG, Choi WS. Rejuvenating effects of facial hydrofilling using restylane vital. Arch Plast Surg. 2015; 42:282–287.